AustralianSuper Pty Ltd Has $268.12 Million Stock Position in Boston Scientific Corporation $BSX

AustralianSuper Pty Ltd raised its stake in Boston Scientific Corporation (NYSE:BSX) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,746,328 shares of the medical equipment provider’s stock after acquiring an additional 47,473 shares during the quarter. Boston Scientific comprises approximately 1.2% of AustralianSuper Pty Ltd’s investment portfolio, making the stock its 12th biggest holding. AustralianSuper Pty Ltd owned approximately 0.19% of Boston Scientific worth $268,124,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at $746,655,000. Parnassus Investments LLC increased its stake in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after buying an additional 6,868,459 shares during the period. Bessemer Group Inc. raised its position in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after acquiring an additional 2,899,653 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after acquiring an additional 2,823,744 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. Barclays lifted their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Truist Financial lowered their price target on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. TD Cowen restated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Robert W. Baird raised their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, UBS Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $123.89.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 80,204 shares of company stock valued at $7,998,563. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $93.74 on Thursday. The firm’s 50 day moving average price is $95.36 and its two-hundred day moving average price is $99.65. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm has a market cap of $138.96 billion, a P/E ratio of 50.13, a PEG ratio of 1.66 and a beta of 0.67.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.